Trevyent NDA Submitted for Pulmonary Arterial Hypertension

Trevyent is a novel device that administers treprostinil in a new parenteral form, using SteadyMed’s PatchPump technology
Trevyent is a novel device that administers treprostinil in a new parenteral form, using SteadyMed’s PatchPump technology

Cardiome Pharma announced that its partner SteadyMed has submitted a New Drug Application (NDA) for Trevyent (treprostinil injection) for the treatment of pulmonary arterial hypertension (PAH).

Trevyent is a novel drug-device product that administers treprostinil in a new parenteral delivery form, using SteadyMed's PatchPump technology. The PatchPump is a single-use, 2-day disposable drug delivery platform that is pre-filled and pre-programmed with treprostinil at the correct administration rate. Sensors located on the PatchPump aid patients through visual and audible cues to demonstrate complete delivery and end of dosing.  

Related Articles

Trevyent contain treprostinil, a vasodilatory prostacyclin analogue. It works primarily through vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.

For more information please call (800) 330-9928 or visit Cardiome.com